Serum Bovine Immunoglobulin Protein Isolate in Improving Quality of Life and Post-Operative Recovery in Patients With Gynecological Cancer After Undergoing Surgery

Overview

Información sobre este estudio

This randomized pilot phase II trial studies how well serum bovine immunoglobulin protein isolate works in improving quality of life and post-operative recovery in patients with gynecological cancer after undergoing surgery. Serum bovine immunoglobulin supplementation may improve the quality of life of patients with gynecological cancer.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Diagnosis of gynecological cancer of any type or strong suspicion for cancer
  • Patients must have begun postoperative oral intake of food prior to registration
  • Had an open laparotomy, laparoscopic surgery, or cancer therapeutic surgery (not a subsequent surgery to manage a postoperative complication) that occurred ≤ 7 days prior to registration and that entailed more than a simple hysterectomy
  • Creatinine ≤ 1.5 x the upper limit of normal (ULN)
  • Absolute neutrophil count ≥ 1500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Ability to complete questionnaire(s) by themselves or with assistance
  • Provide informed written consent
  • Negative (serum) pregnancy test done ≤ 7 days prior to randomization, for women of childbearing potential only
  • Willing to provide mandatory baseline blood samples for correlative research purposes

Exclusion Criteria:

  • Symptomatic and/or untreated brain metastases
  • Ongoing parenteral nutrition (receiving intravenous nutrition support at the time of enrollment); note: patients may be receiving maintenance intravenous (IV) fluids
  • Current enrollment in any other trial that entails the concurrent administration of any other agent designed to enhance postoperative recovery
  • Allergy to beef

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Aminah Jatoi, M.D.

Cerrado para la inscripción

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publicaciones

Publications are currently not available
.
CLS-20112310

Mayo Clinic Footer